Keyphrases
Antitumor
100%
Prostate Tumor
100%
Human Prostate
100%
Tumor-infiltrating Lymphocytes
100%
Adoptive Cell Therapy
100%
Tumor Reactivity
100%
Lymphocyte Culture
36%
Autologous Tumors
18%
Study Support
9%
Melanoma
9%
Solid Tumors
9%
Tumor Specimens
9%
Rapid Expansion
9%
Programmed Death-ligand 1 (PD-L1)
9%
Previously Treated
9%
Immunogenic
9%
Causes of Mortality
9%
Metastatic Melanoma
9%
Adoptive Transfer
9%
Tim-3
9%
Prostate Carcinoma
9%
Lung Carcinoma
9%
Functional Tumor
9%
CD28
9%
Advanced Prostate Cancer
9%
T Cell Subsets
9%
Co-culture Assay
9%
Prostate Cancer Patients
9%
Radical Prostatectomy
9%
Co-inhibitory
9%
Immunosuppressive Microenvironment
9%
Patients with Prostate Cancer
9%
Tumor-infiltrating Lymphocyte Therapy
9%
Differentiation Status
9%
Practice Conditions
9%
Good Manufacturing Practice
9%
Medicine and Dentistry
Cell Therapy
100%
Neoplasm
100%
Prostate Tumor
100%
Tumor Infiltrating Lymphocyte
100%
Lymphocyte Culture
33%
Prostate Cancer
25%
Malignant Neoplasm
8%
Solid Malignant Neoplasm
8%
Immunotherapy
8%
Immunosuppressive Drug
8%
Metastatic Melanoma
8%
Adoptive Transfer
8%
Lung Carcinoma
8%
T Cell Subset
8%
Prostatectomy
8%
Prostate Adenocarcinoma
8%
Melanoma
8%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Prostate Tumor
100%
Prostate Cancer
20%
Malignant Neoplasm
6%
Melanoma
6%
Solid Malignant Neoplasm
6%
Immunotherapy
6%
Immunosuppressive Agent
6%
Lung Carcinoma
6%
Metastatic Melanoma
6%
Prostate Adenocarcinoma
6%
Good Manufacturing Practice
6%
Immunology and Microbiology
Tumor-Infiltrating Lymphocytes
100%
Immunosuppressive Drug
8%
Immunotherapy
8%
CD28
8%
Coculture
8%
T Cell Subset
8%